<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149030</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-004</org_study_id>
    <nct_id>NCT02149030</nct_id>
  </id_info>
  <brief_title>Effectiveness of Cervical Screening in HPV Vaccinated Women</brief_title>
  <acronym>HPV-004</acronym>
  <official_title>Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Society of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tampere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to identify whether or not being informed infrequently
      results about screening is: 1) At least as safe and accurate as frequently obtaining all
      information from the present combination of opportunistic/organized cervical screening by
      comparing regimen results of three screening visits at the ages of 22, 25 and 30 years (Arm
      A1) vs. results of one screening visit at the age of 30 years (Arm A2) in Human
      papillomavirus (HPV) vaccinated young women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Altogether 16.500 1992-1995 born women vaccinated with the bi-valent human papillomavirus
      type 16 and 18 (HPV16/18) vaccine as adolescents either at the age of 12 to 15 or at the age
      of 18 will be invited to an effectiveness trial at the age of 22 years, and randomized into
      Arms A1 and A2, and A3, respectively.

      Cervical samples and cervico-vaginal self-samples rinsed in first-void urine will be analysed
      for HPV and C. trachomatis DNA with MGP primer system followed by MALDITOF mass spectrometry
      on the SEQUENOM platform (HPV) and the Abbott™ PCR (Chlamydia trachomatis), respectively.

      With assumed &gt;50% participation the trial has 80% power to show non-inferiority of the
      infrequent vs. the frequent screening information.

      A one-way (participant) blinded interim analysis among the 1992-born study participants in A1
      and A3 arms, who have attended the 2nd study visit at the age of 25 years, will be performed
      in 2017 for assuring no statistically significant differences in the cervical intraepithelial
      neoplasia grade 2/3 (CIN2/CIN3) incidences of the two arms.

      At the study end testing the null hypotheses of no difference in the incidence of the CIN2/3
      end-points between the A1 and A2 intervention arms will be done using the Mantel-Haenszel one
      degree of freedom chi-square statistics.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of intraepithelial neoplasia grade 2/3 (CIN2/3).</measure>
    <time_frame>2017(interim), 2026 (final analysis). Participants will be followed for the duration of the study until 2026, an expected average of 9 years.</time_frame>
    <description>1a) No marked difference in the incidence of CIN2/3 between arms A1 (participants frequently informed of the cytological results) and A3 (participants not informed of the cytological findings at the age of 22) (interim analysis). 1b) No difference in the incidence of CIN2/3 between arms A1 (participants frequently informed of the cytological results) and A2 (participants infrequently informed of the cytological results).
The participants will be followed for 9 years starting from the year they turn 22. For 1992 born the follow-up will start in 2014 and end in 2023. For 1995 born the follow-up will start in 2017 and end in 2026.
The interim analysis will include only 1992 cohort. The final analysis will include all cohorts (1992, 1993, 1994, 1995).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">7500</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A2) infrequent information of screening results, only at the age 30 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytological screening in A1 and A3</intervention_name>
    <description>Cytological screening.</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HPV 16/18 vaccinated. Born 1992-1995.

        Exclusion Criteria:

          -  Immunocompromising disease. HPV 6/11/16/18 vaccination.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti Lehtinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HUS</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Hämeenlinna</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Iisalmi</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Jämsä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kajaani</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kemi</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kouvola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Lappeenranta</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Lohja</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Mikkeli</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THL</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Porvoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Rauma</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Rovaniemi</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Salo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Savonlinna</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Vaasa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Vammala</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Varkaus</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema: Tampereen yliopisto</name>
      <address>
        <city>Äänekoski</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tampere</investigator_affiliation>
    <investigator_full_name>Matti Lehtinen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

